Abstract:Glaucoma is a progressive neuropathy characterized by loss of vision as a result of the death of retinal ganglion cells (RGCs). There are currently no effective neuroprotectants to treat this disorder. In this series of studies, we used LINGO-1 antagonists, Nogo-66 receptor (NgR1) antagonists, sNgR-Fc, and brain-derived neurotrophic factor (BDNF) to study the neuroprotection of RGCs in a rat glaucoma model with chronic ocular hypertension. LINGO-1 is a functional member of the NgR1/TROY and the P75 signaling complexes that prevent axonal regeneration by activating RhoA in the central nervous system (CNS). NgR1 mediates the inhibition of axonal regeneration in the presence of three myelin proteins including Nogo-A, myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein in the CNS. LINGO-1 was expressed in RGCs and increased after the induction of ocular hypertension. Blocking LINGO-1 function with LINGO-1 soluble protein, LINGO-1-Fc, and LINGO-1 mAb 1A7 significantly promoted RGC survival 2 and 4 weeks after the induction of ocular hypertension and also after optic nerve transection. LINGO-1 formed a receptor complex with TrkB and negatively regulated its activation in the retina after ocular hypertension injury. Blocking LINGO-1 function with LINGO-1-Fc or 1A7 upregulated TrkB phosphorylation after high intraocular pressure injury. BDNF antibody significantly blocked the neuroprotection of LINGO-1-Fc on RGC survival. Similarly, in combination with BDNF, LINGO-1-Fc provided significantly more protection to RGCs in the 4-week glaucoma animals. Thus, LINGO-1 antagonists protect RGCs by regulating the BDNF and TrkB signaling in glaucoma. NgR1 was expressed in RGCs and increased after the induction of ocular hypertension. There was synaptic degeneration of RGCs already detected in the early stage under the elevated intraocular pressure, which preceded cell death in the early stage. The upregulation of Nogo-A may be a possible mechanism of RGC death and synapse degeneration in glaucoma. Soluble (s) NgR-Fc significantly promoted RGC survival at 2 and 4 weeks after ocular hypertension and also after optic nerve transection. Furthermore, sNgR-Fc relieved synaptic degeneration at 5 days, and at 2 and 4 weeks. This suggests that there indeed may be an opportunity to rescue RGCs that are undergoing synaptic alteration, but not yet committed to die. These data suggest that the antagonists of LINGO-1 and NgR1 may provide an attractive therapeutic strategy to prevent the degeneration of RGCs and synapses in glaucoma.

Circular RNA-based therapy provides sustained and robust neuroprotection for retinal ganglion cells

Targeting Circular RNA-Glra2 Alleviates Retinal Neurodegeneration Induced by Ocular Hypertension

Identification of circular RNA-Dcaf6 as a therapeutic target for optic nerve crush-induced RGC degeneration

Targeting Circular RNA-ZRANB1 for Therapeutic Intervention in Retinal Neurodegeneration

Sustained neurotrophic factor cotreatment enhances donor and host retinal ganglion cell survival in mice

Silencing of circular RNA‐ZYG11B exerts a neuroprotective effect against retinal neurodegeneration

CircXPO5 Plays a Neuroprotective Function in the Lateral Geniculate Nucleus of Glaucoma by Regulating GRIN2A

Circular Rnas: Novel Promising Biomarkers In Ocular Diseases

Protection of Ciliary Neurotrophic Factor for Retinal Ganglion Cells

CircRNA in Ocular Neovascular Diseases: Fundamental Mechanism and Clinical Potential.

Retina as a window to cerebral dysfunction following studies with circRNA signature during neurodegeneration

Neuroprotection of Retinal Ganglion Cells in Glaucoma by Blocking Lingo-1 Function or Using A Nogo-66 Receptor Antagonist

Novel engineered, membrane-localized variants of vascular endothelial growth factor (VEGF) protect retinal ganglion cells: a proof-of-concept study

Extracellular Vesicle–Mediated Delivery of Circular RNA SCMH1 Promotes Functional Recovery in Rodent and Nonhuman Primate Ischemic Stroke Models

Topical recombinant human Nerve growth factor (rh-NGF) is neuroprotective to retinal ganglion cells by targeting secondary degeneration

Schwann Cell-Derived Extracellular Vesicles As a Potential Therapy for Retinal Ganglion Cell Degeneration.

CircRNA is a Rising Star in Researches of Ocular Diseases

Circular RNA-ZNF609 regulates retinal neurodegeneration by acting as miR-615 sponge.

Penumbra-targeted CircOGDH Sirna-Loaded Nanoparticles Alleviate Neuronal Apoptosis in Focal Brain Ischaemia.

A Dual‐Drug Nanohybrid System Incorporating Nimodipine and Brain‐Derived Neurotrophic Factor Promotes Retinal Ganglion Cells Survival

Bioactive Glial-Derived Neurotrophic Factor from a Safe Injectable Collagen–Alginate Composite Gel Rescues Retinal Photoreceptors from Retinal Degeneration in Rabbits